Clinical trial
MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or…
NCT00374296 · Mirati Therapeutics Inc., Industry · Terminated
Key facts
| NCT number | NCT00374296 |
|---|---|
| Title | MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease |
| Official title | A Phase II Study of MGCD0103 (MG-0103) in Patients With Acute Myelogenous Leukemia/High Risk MDS Who Are Elderly and Have Previously Untreated Disease or Who Are Adult and Have Relapsed/Refractory Disease |
| Lead sponsor | Mirati Therapeutics Inc., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelogenous Leukemia, Acute, Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | MGCD0103 |
| Enrollment | 35 |
| Start date | Sep 1, 2006 |
| Primary completion | Sep 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Sep 11, 2006 |
| Last update posted | Jul 1, 2015 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: